AMRN News 1.76 07/01/2014 04:26:39 Amarin Corporation Plc (A

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amarin Corporation Plc (AMRN) 1.76 $AMRN

Rick Harrison of Television's "Pawn Stars®" Discusses His Revelations on Seeking Treatment for His Very High Triglycerides in National Awareness Campaign
PR Newswire - Wed Jun 25, 5:30AM CDT
Amarin Corporation, plc (Nasdaq: AMRN), today announced a national partnership with Rick Harrison, star of the hit television show "Pawn Stars®," in launching Lower My Trigs(TM), a national awareness campaign about seeking treatment for very high triglycerides (VHTG) (> 500 mg/dL), a problem faced by up to four million Americans. Amarin has engaged Harrison as a spokesperson for the campaign to inform patients and family members, their physicians and other health care professionals about the health risks of very high triglycerides and the importance of patients discussing available treatment options with their physician.

Of These 3 Battleground Biotech Stocks, 1 Is a Buy
Brian Orelli, The Motley Fool - Motley Fool - Tue Jun 24, 9:26AM CDT
The Biotech Banter crew is getting into the World Cup spirit, looking at foreign biotechs to see whether they're investable. First up: Amarin has a drug on the market, but unfortunately its fish oil Vascepa has struggled to gain much...

Biotech 101: Off-Label Prescriptions
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 8:21PM CDT
When the Food and Drug Administration approves a drug, it's given a label, although there's no sticky stuff on the back and it's not attached to the bottle. Drug labels are multipage documents that list everything from the chemical description of the...

Amarin Up 5.2%, Shares Break Through Resistance (AMRN)
Comtex SmarTrend(R) - Thu Jun 19, 10:38AM CDT
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 5.2% to $1.63 on 1.4x average daily volume. Thus far today, Amarin has traded 2.2 million shares, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.2% to the Dow's -0.2%) and outperformed the S&P 500 (5.2% to the S&P's -0.1%) during today's trading.

Stock Watchout on Biotech Industry -- Research on Isis Pharma, Pharmacyclics, Amarin, and Prana Biotechnology
PR Newswire - Wed Jun 11, 6:10AM CDT
The US markets on Tuesday, June 10, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,945.92, up 0.02% and the NASDAQ Composite closed at 4,338.00, up 0.04%. The S&P 500 finished the session 0.02% lower at 1,950.79. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 692.83, up 0.21%, with the index advancing 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Pharmacyclics Inc. (NASDAQ: PCYC), Amarin Corp. PLC (NASDAQ: AMRN) and Prana Biotechnology Ltd (NASDAQ: PRAN). Free technical research on ISIS, PCYC, AMRN and PRAN can be downloaded upon signing up at:

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)
Marketwire - Wed Jun 11, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the publication of a retrospective analysis of patient cases that examined the effect on lipid parameters in hyperlipidemic patients who were switched from Lovaza® (omega-3-acid ethyl esters) capsules, a mixture of omega fatty acids, to Vascepa® (icosapent ethyl) capsules, the only pure-EPA prescription omega-3 product, to potentially achieve better outcomes in triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) levels.1 During the studied period, most of the 14 patients switched to Vascepa experienced reductions in levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C).

Amarin to Present at the Goldman Sachs 2014 Global Healthcare Conference
Marketwire - Thu Jun 05, 2:15AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Goldman Sachs 2014 Global Healthcare Conference on Wednesday, June 11, 2014, at 3:20 p.m. PT.

Amarin to Present at the Jefferies 2014 Global Healthcare Conference
Marketwire - Thu May 29, 7:03AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014, at 8:00 a.m. ET.

High Triglyceridemia Therapeutics Pipeline Review 2014 - 16 Companies & 19 Drug Profiles
M2 - Tue May 20, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bkl7cl/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Tekmira Pharmaceuticals Corp. - Actavis plc - Isis Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Amarin Corporation plc - Alnylam Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cardax Pharmaceuticals, Inc. - Essentialis, Inc. - Epax AS - Pharmena SA - FORMAC Pharmaceuticals N.V. - Omthera Pharmaceuticals, Inc. - Poxel SA - Acasti Pharma Inc. Drug Profiles - icosapent ethyl - omega-3-carboxylic acids - diazoxide CR - AKR-963 - TRIA-662 - ISIS-APOCIIIRx - NKPL-66 - pradigastat sodium - CAT-2003 - fenofibrate - bezafibrate ER - CDX-085 - CAT-2000 Series - AS-1708727 - MAT-9001 - Drug For Hypertriglyceridemia - ALN-ANG - Small Molecule Farnesoid X Receptor Agonist for Gastrointestinal, Metabolic and Cardiovascular Diseases - Peptides for Dyslipidemic and Vascular Disorders For more information visit http://www.researchandmarkets.com/research/bkl7cl/high

AstraZeneca's Fishy FDA Approval
Brian Orelli, The Motley Fool - Motley Fool - Mon May 19, 5:28PM CDT
The Food and Drug Administration recently approved AstraZeneca 's Epanova, adding it to the growing list of omega-3 fish oil drugs that includes GlaxoSmithKline 's Lovaza and Amarin 's Vascepa. In the following video, senior biotech...

Ligand-AstraZeneca Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 19, 5:00PM CDT
Ligand Pharmaceuticals Inc. (LGND) and AstraZeneca signed a licensing and research deal.

Technical Pulse on Active Equities -- Research on Amarin, Abbott Laboratories, Apple, and T-MobileUS
PR Newswire - Fri May 16, 9:23AM CDT
The trading session on Thursday, May 15, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,446.81, down 1.01% and the NASDAQ Composite closed at 4,069.29, down 0.76%. The S&P 500 finished the day 0.94% lower at 1,870.85. The losses were broad based as nine out of ten sectors finished on a negative note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Amarin Corp. PLC (NASDAQ: AMRN), Abbott Laboratories (NYSE: ABT), Apple Inc. (NASDAQ: AAPL) and T-Mobile US Inc. (NYSE: TMUS). Free technical research on AMRN, ABT, AAPL and TMUS can be downloaded upon signing up at:

Why Amarin (AMRN) Stock Is Plummeting Today
at The Street - Thu May 15, 1:37PM CDT
Amarin (AMRN) is down big after announcing private exchange transaction of outstanding senior notes.

Why Amarin Corporation PLC Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Thu May 15, 12:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amarin , a biopharmaceutical company...

Amarin Down 8.6%, Shares Slide into the Red (AMRN)
Comtex SmarTrend(R) - Thu May 15, 10:09AM CDT
Amarin (NASDAQ:AMRN) is one of today's worst performing low-priced stocks, down 8.6% to $1.39 on 1.4x average daily volume. Thus far today, Amarin has traded 2.4 million shares, vs. average volume of 1.7 million shares per day. The stock has underperformed the Dow (-8.6% to the Dow's -0.9%) and underperformed the S&P 500 (-8.6% to the S&P's -1.0%) during today's trading.

Amarin Announces Private Exchange Transactions Regarding Outstanding Senior Exchangeable Notes
GlobeNewswire - Thu May 15, 5:19AM CDT
Amarin Corporation plc (Nasdaq:AMRN) ("Amarin" , announced today that it and its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer" , have entered into separate, privately negotiated exchange agreements with certain holders of its outstanding 3.50% Exchangeable Senior Notes due 2032 issued on January 9, 2012 (the "2012 Notes" pursuant to which the Issuer will exchange $118.734 million in aggregate principal amount of the 2012 Notes for $118.734 million in aggregate principal amount of new 3.50% May 2014 Exchangeable Senior Notes due 2032 (the "2014 Notes" . Following the closing of these transactions, $31.266 million in aggregate principal amount of the 2012 Notes will remain outstanding with terms unchanged. The 2014 Notes will be exchangeable into American Depositary Shares of Amarin ("ADSs" at the option of the holders at an initial exchange rate of 384.6154 ADSs per $1,000 principal amount of 2014 Notes (equivalent to an initial exchange price of approximately $2.60 per ADS), subject to adjustment in certain circumstances. The exchange is expected to close on May 20, 2014, subject to customary closing conditions.

Downgrade Alert for Amarin (AMRN)
Comtex SmarTrend(R) - Mon May 12, 7:11AM CDT
Amarin (NASDAQ:AMRN) was downgraded from Buy to Neutral at Citigroup today. The stock closed yesterday at $1.51 on volume of 2.4 million shares, above average daily volume of 1.8 million. Amarin Corporation PLC is a clinical-stage biopharmaceutical company. The Company researches, develops, and commercializes drugs for the treatment of hypertriglyceridemia, central nervous system disorders, and cardiovascular diseases.

Health Care Stocks to Watch Today: Amarin Corporation plc, Jazz Pharmaceuticals, and Vanda Pharmaceu
George Budwell, The Motley Fool - Motley Fool - Fri May 09, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Amarin ,  Jazz Pharmaceuticals and  Vanda Pharmaceuticals .   Amarin reports first-quarter earnings The much-maligned biotech Amarin reported...

Amarin Reports First Quarter 2014 Financial Results and Provides Update on Operations
GlobeNewswire - Fri May 09, 6:01AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2014, and provided an update on company operations.

Amarin to Report First Quarter 2014 Results and Host Conference Call on May 9, 2014
GlobeNewswire - Mon May 05, 8:41AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2014 financial results and provide an operational update on Friday, May 9, at 8:00 a.m. ET. The conference call will follow the anticipated release of the company's first quarter 2014 financial results earlier that day.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 53

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 292

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 49

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 26

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 150

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 135

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 32

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 69

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 67

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading

Top 5 Most Recently Viewed Articles

Artprice News Revolutionizes Global Art Market Information

Updated Category News Views 237

Artprice News Launch: A New Chapter in Art Market Reporting Artprice by Artmarket has introduced a groundbreaking initiative with the launch of Artprice News, marking a significant evolution in the landscape of art market information. This innovative news agency is tailored exclusively for the art world, broadcasting valuable insights in 11 languages and spanning 122...

Continue Reading
U-BX Technology Ltd. Responds to Nasdaq Notification on Listing

Updated Category News Views 211

U-BX Technology Ltd. Responds to Nasdaq Notification U-BX Technology Ltd. (NASDAQ: UBXG), recognized as a frontrunner in offering innovative services powered by artificial intelligence to the insurance sector, recently informed stakeholders regarding important notifications received from The Nasdaq Stock Market LLC. Details of Nasdaq Notification Letters On a recent date,...

Continue Reading
Understanding Investor Rights in Newmont Securities Class Action

Updated Category News Views 370

Understanding the Basics of the Newmont Class Action Investors who have sustained losses exceeding $50,000 in Newmont Corporation should take heed of an active class action. This legal effort aims to provide relief for those affected by adverse developments within the company. Faruqi & Faruqi, LLP, a prominent securities law firm, is at the forefront of this investigation...

Continue Reading
Tarte's Record-Breaking Collab: 60 Seconds to Sellout

Updated Category News Views 129

When Makeup Meets Pajamas: The Perfect Storm Picture this: a makeup brand and a lifestyle label dreaming up a collaboration that sends consumers into a full-blown frenzy. In a whirlwind that lasted just 60 seconds, tarte's latest partnership with Roller Rabbit blazed through stock, cementing its place as a record-breaking phenomenon. Maureen Kelly, tarte’s intrepid CEO,...

Continue Reading
What Lessons Can Traditional Investors Learn From the Rise of Ethereum?

Updated Category Crypto Views 3176

Turn the clock back a few decades, and investors on Wall Street would laugh if you tried to pitch the concept of blockchain to them. It’s one of those ideas that sound like they’d technically work but would be impossible to practically execute. Yet today, blockchain and cryptocurrency exist and are proof that the skeptics were wrong. Sadly, many traditional investors...

Continue Reading